BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Hungary
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 11 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 29 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
- 29 Aug 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Sep 2016.